NIH intends to award a non-competitive purchase order to Purdue University’s Purdue Institute for Drug Discovery for synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 in support of an NIH Bench-to-Bedside study on red cell-specific SYK inhibitors for sickle cell disease. The work is a continuation of project-specific medicinal chemistry performed by Dr. Philip S. Low’s laboratory, which has prior design and synthesis experience with the candidate compounds. NIH states that using another source would require duplicating prior research and create delay and technical risk, making Purdue the only reasonably available source for the Year 1 requirement. Performance is associated with Purdue Institute for Drug Discovery, 575 Stadium Mall Drive, West Lafayette, IN 47907. The applicable NAICS code is 325411, and the requirement is not set aside for small business.